Hemosiderosis: an unrecognized complication in renal allograft recipients

Transplantation
K V Rao, W R Anderson

Abstract

During the past decade, 258 patients received 293 renal transplants at Hennepin County Medical Center Minneapolis, Minnesota. Twenty-three of these patients had a pretransplant liver biopsy. Thirty-six patients had liver biopsies done during the post-transplant period. Liver tissue at autopsy was available from 24 patients who died after receiving a kidney transplant. Systematic analysis of the biopsy and autopsy specimens with appropriate tissue stains showed significant iron deposition (3+ to 4+) within the hepatic parenchymal cells in 1 of the 23 (4%) pretransplant biopsies and 17 of the 60 (28%) post-transplant specimens (P = 0.02). Eight of the 17 (47%) patients with post-transplant hemosiderosis also exhibited histological features of liver cirrhosis. As hemosiderosis is reversible with intermittent phlebotomies, early recognition and adequate management are highly desirable. We suggest that the serum ferritin level, which is a reliable index of body iron stores, should be monitored in all patients at periodic intervals following renal transplantation.

Citations

Jan 1, 1991·Gastrointestinal Radiology·F H MillerR M Gore
Oct 3, 2002·Seminars in Dialysis·Nasimul Ahsan, K Venkateswara Rao
May 1, 1992·Transplant International : Official Journal of the European Society for Organ Transplantation·Z KadryR R Gifford
Jan 3, 2001·Transplantation Proceedings·C JorgeD Machado
Dec 29, 1998·Transplantation Proceedings·B RamakrishnaA Date
Aug 1, 1990·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J M LazarusJ Newell
Jun 26, 2014·Transplant International : Official Journal of the European Society for Organ Transplantation·Benedikt SchaeferHeinz Zoller
Feb 7, 2021·BMJ Case Reports·Binayak UpadhyayAśok C Antony

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.